Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

Hepion Pharmaceuticals (NASDAQ:HEPA) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial.A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study. The failure of the study comes as it couldn’t reach the planned 336 patients. Instead, it only got to 151 patients.On top of this, Hepion Pharmaceuticals is struggling with resources as the company is exploring strategic alternatives. This didn’t leave it with enough room ...